SCHEMBL3704245

SCHEMBL3704245

O=C(O)NCc1ccc(Cl)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.56
NAMPT P43490 2/20 0.54
CYP2C9 P11712 1/20 0.54
ALDH1A1 P00352 3/20 0.54
KDM4E B2RXH2 2/20 0.53
GAA P10253 2/20 0.53
MAPT P10636 1/20 0.53
FAAH O00519 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.49
NAPRT Q6XQN6 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
KDM1A O60341 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
HDAC1 Q13547 2/20 0.46
OXTR P30559 1/20 0.46
AVPR1A P37288 1/20 0.46
FPR2 P25090 1/20 0.45
FFAR1 O14842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2641908 0.84 L3MBTL1 (0.52) L3MBTL1NAMPTCYP2C9ALDH1A1KDM4E
SCHEMBL2641902 0.84 L3MBTL1 (0.52) L3MBTL1NAMPTCYP2C9ALDH1A1KDM4E
SCHEMBL2632301 0.84 ALDH1A1 (0.57) L3MBTL1NAMPTCYP2C9ALDH1A1KDM4E
SCHEMBL29811285 0.84 ALDH1A1 (0.57) L3MBTL1NAMPTCYP2C9ALDH1A1KDM4E
SCHEMBL625919 0.84 CYP2C9 (0.61) L3MBTL1NAMPTCYP2C9ALDH1A1KDM4E
SCHEMBL20641195 0.83 NAMPT (0.47) L3MBTL1NAMPTCYP2C9ALDH1A1KDM4E
SCHEMBL4440918 0.83 NPC1 (0.58) L3MBTL1NAMPTCYP2C9ALDH1A1KDM4E
SCHEMBL8837372 0.82 L3MBTL1 (0.74) L3MBTL1NAMPTCYP2C9KDM4EGAA
SCHEMBL21492287 0.82 GAA (0.47) L3MBTL1NAMPTCYP2C9ALDH1A1KDM4E
SCHEMBL5012151 0.81 FAAH (0.61) L3MBTL1NAMPTCYP2C9ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4382519-A1 CYCLIN K DEGRADATION AGENT Adlai Nortye Biopharma Co., Ltd. (CN) 2024-06-12 EP disclosed
US-11945806-B2 Stabilization of amyloidogenic immunoglobulin light chains THE SCRIPPS RESEARCH INSTITUTE 2024-04-02 US disclosed
WO-2023244563-A1 ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE AMYGDALA NEUROSCIENCES, INC. (US) 2023-12-21 WO disclosed
US-20230399299-A1 ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE AMYGDALA NEUROSCIENCES, INC. (US) 2023-12-14 US disclosed
WO-2023140640-A1 HETEROARYL DERIVATIVE AND USES THEREOF 한양대학교 산학협력단 2023-07-27 WO disclosed
US-20230159523-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) 2023-05-25 US disclosed
EP-4141003-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF Shenzhen Zhongge Biological Technology Co., Ltd. (CN) 2023-03-01 EP disclosed
US-20220204485-A1 STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS THE SCRIPPS RESEARCH INSTITUTE 2022-06-30 US disclosed
EP-3946604-A1 BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS The Scripps Research Institute (US) 2022-02-09 EP disclosed
EP-3535258-B1 SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-11-24 EP disclosed
US-9168249-B2 Substituted dihydropyrazolones for treating cardiovascular and hematological diseases BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-10-27 US disclosed
US-20150148381-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-05-28 US disclosed
US-8987261-B2 Substituted dihydropyrazolones for treating cardiovascular and hematological diseases BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-24 US disclosed
US-8653111-B2 Substituted dihydropyrazolones for treating cardiovascular and hematological diseases BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-18 US disclosed
US-20140031329-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-01-30 US disclosed
US-8389520-B2 Substituted dihydropyrazolones for treating cardiovascular and hematological diseases BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-03-05 US disclosed
US-20120121727-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-17 US disclosed
US-20100305085-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-12-02 US disclosed
EP-2054413-A2 PYRIDOBENZAZEPINE COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION Millennium Pharmaceuticals, Inc. (US) 2009-05-06 EP disclosed
WO-2008021038-A2 PYRIDOBENZAZEPINE COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031329-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES THPO, PFKP, DCK L3MBTL1 3037/4885NAMPT 2678/4885CYP2C9 1749/4885
US-20220204485-A1 STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS TTR, MAP1LC3B, SAAL1 L3MBTL1 336/4885NAMPT 2905/4885CYP2C9 3219/4885
US-20100305085-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES THPO, PFKP, HPGDS L3MBTL1 2921/4885NAMPT 2619/4885CYP2C9 662/4885
US-20120121727-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES THPO, PFKP, DCK L3MBTL1 3037/4885NAMPT 2678/4885CYP2C9 1749/4885
US-20230399299-A1 ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE ALDH1A1, ALDH2, ALDH3A1 L3MBTL1 3358/4885NAMPT 525/4885CYP2C9 331/4885
US-20230159523-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF NCOA4, CCDC47, CCDC6 L3MBTL1 1721/4885NAMPT 3483/4885CYP2C9 3759/4885
US-11945806-B2 Stabilization of amyloidogenic immunoglobulin light chains TTR, MAP1LC3B, SAAL1 L3MBTL1 336/4885NAMPT 2905/4885CYP2C9 3219/4885
US-20150148381-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES THPO, PFKP, DCK L3MBTL1 3037/4885NAMPT 2678/4885CYP2C9 1749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.